• bitcoinBitcoin(BTC)$64,534.00-1.39%
  • ethereumEthereum(ETH)$1,805.45-1.19%
  • tetherTether(USDT)$1.00-0.02%
  • binancecoinBNB(BNB)$590.39-1.14%
  • usd-coinUSDC(USDC)$1.000.00%
  • rippleXRP(XRP)$0.95-1.18%
  • solanaSolana(SOL)$71.27-0.83%
  • tronTRON(TRX)$0.302612-1.79%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.060.00%
  • HyperliquidHyperliquid(HYPE)$67.27-0.92%
  • zcashZcash(ZEC)$890.92-1.90%
  • moneroMonero(XMR)$491.04-1.71%
  • dogecoinDogecoin(DOGE)$0.058538-0.62%
  • leo-tokenLEO Token(LEO)$9.201.23%
  • USDSUSDS(USDS)$1.000.00%
  • whitebitWhiteBIT Coin(WBT)$62.48-1.29%
  • chainlinkChainlink(LINK)$9.13-1.24%
  • cardanoCardano(ADA)$0.152042-1.40%
  • RainRain(RAIN)$0.00714895.23%
  • stellarStellar(XLM)$0.137614-0.96%
  • Ethena USDeEthena USDe(USDE)$1.000.00%
  • daiDai(DAI)$1.000.04%
  • nearNEAR Protocol(NEAR)$3.180.48%
  • bitcoin-cashBitcoin Cash(BCH)$206.13-1.08%
  • litecoinLitecoin(LTC)$44.53-2.45%
  • CantonCanton(CC)$0.0837294.02%
  • avalanche-2Avalanche(AVAX)$7.11-2.31%
  • uniswapUniswap(UNI)$5.140.57%
  • tether-goldTether Gold(XAUT)$3,844.310.54%
  • USD1USD1(USD1)$1.000.08%
  • the-open-networkGram (prev. Toncoin)(GRAM)$1.05-1.28%
  • suiSui(SUI)$0.72-1.01%
  • Ripple USDRipple USD(RLUSD)$1.000.01%
  • Global DollarGlobal Dollar(USDG)$1.000.01%
  • hedera-hashgraphHedera(HBAR)$0.057920-0.89%
  • paypal-usdPayPal USD(PYUSD)$1.00-0.01%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.150.15%
  • shiba-inuShiba Inu(SHIB)$0.000004-1.46%
  • quant-networkQuant(QNT)$155.462.34%
  • BittensorBittensor(TAO)$189.35-1.30%
  • crypto-com-chainCronos(CRO)$0.042683-3.00%
  • Circle USYCCircle USYC(USYC)$1.140.00%
  • Spiko Amundi Overnight Swap Fund (EUR)Spiko Amundi Overnight Swap Fund (EUR)(EURSAFO)$1.12-0.11%
  • MemeCoreMemeCore(M)$0.82-0.64%
  • okbOKB(OKB)$84.97-3.52%
  • pax-goldPAX Gold(PAXG)$3,846.660.51%
  • aaveAave(AAVE)$109.372.41%
  • Falcon USDFalcon USD(USDF)$1.000.03%
  • BlackRock USD Institutional Digital Liquidity FundBlackRock USD Institutional Digital Liquidity Fund(BUIDL)$1.000.00%
  • United StablesUnited Stables(U)$1.00-0.03%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal

May 10, 2024
in Market & News
Reading Time: 2 mins read
A A
Novavax Soars on .2 Billion Sanofi Vaccine Licensing Deal
ShareShareShareShareShare

(Bloomberg) — Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot.

Most Read from Bloomberg

YOU MAY ALSO LIKE

Florida man who swallowed $769,000 in Tiffany diamonds found guilty

Apple Bets on Siri AI Apps as the Main Draw for Its Smart Glasses – Bloomberg.com

Novavax will receive $500 million in upfront payments as well as a further $700 million if all development, regulatory and launch milestones are met, according to a statement Friday. Novavax, which will receive tiered royalties on any vaccine sales, said Sanofi is also taking a minority equity stake of about 5% in the US company.

Novavax shares rose as much as 146% in early trading in New York and the stock is on track for its biggest one-day increase on record. The stock was trading at $10.02 a share on Friday, although this is still well off a peak of about $320 in early 2021.

The pact links two big players in the vaccine world that both missed out on the rush to develop and commercialize Covid shots quickly during the pandemic. Amid various setbacks, Sanofi and Novavax ceded tens of billions of dollars in sales to nimbler messenger-RNA developers including the Pfizer-BioNTech alliance and Moderna Inc.

Now, Sanofi will have the rights to drive sales of Novavax’s Covid-19 shot worldwide from next year, except for in India, Japan and South Korea, where Novavax already has advance purchasing agreements. The French drugmaker also has the sole license to use Novavax’s protein-based Covid shot in combination with its flu shot, which it said will offer patients “enhanced convenience and protection against two serious respiratory viruses.”

Sanofi will also have a non-exclusive license to use Novavax’s Matrix-M adjuvant in other vaccine products. Novavax will still have the right to develop its own combined Covid-flu vaccine at its own cost.

Shares of Sanofi rose slightly in early trading in Paris. The stock was down about 5% in the past 12 months through Thursday’s close.

The deal is a boost for Novavax which is in the midst of restructuring its business after a difficult 2023 when it had to issue a going concern warning about its ability to continue operating. Novavax reported a first-quarter net loss of $148 million, compared with a $294 million loss a year earlier.

At first glance the deal seems surprising for Sanofi but it’s likely a strategic move, said Mila Bankovskaia, a Bloomberg Intelligence analyst.

“Moderna and Pfizer are both assessing mRNA-based combination vaccines, and though Sanofi believes its non mRNA-based flu product won’t be improved, the potential to offer a non-mRNA-based combination as an alternative looks a sensible move,” she said.

(Updates with shares.)

Most Read from Bloomberg Businessweek

©2024 Bloomberg L.P.

Credit: Source link

ShareTweetSendSharePin

Related Posts

Florida man who swallowed 9,000 in Tiffany diamonds found guilty
Market & News

Florida man who swallowed $769,000 in Tiffany diamonds found guilty

November 16, 2026
Apple Bets on Siri AI Apps as the Main Draw for Its Smart Glasses – Bloomberg.com
Market & News

Apple Bets on Siri AI Apps as the Main Draw for Its Smart Glasses – Bloomberg.com

November 16, 2026
King tides flood communities along both U.S. coasts
Market & News

King tides flood communities along both U.S. coasts

November 16, 2026
Opposition leader makes daring return to Venezuela
Market & News

Opposition leader makes daring return to Venezuela

November 16, 2026
Next Post
Palestinians set up camp in a central Gaza coastal town fearing an assault on Rafah

Palestinians set up camp in a central Gaza coastal town fearing an assault on Rafah

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
NIKE Stock: What We Expect From The Upcoming Investor Days (NYSE:NKE)

NIKE Stock: What We Expect From The Upcoming Investor Days (NYSE:NKE)

November 14, 2026
An immigrant farmer fights to keep his American dream alive

An immigrant farmer fights to keep his American dream alive

November 9, 2026
Dan Ives Cuts Nvidia Price Target, But Stays Bullish Post-Huang

Dan Ives Cuts Nvidia Price Target, But Stays Bullish Post-Huang

November 15, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!